Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Shares Traded Last Trade
  12.20 0.85% 1,439.60 9,432,627 16:35:16
Bid Price Offer Price High Price Low Price Open Price
1,440.80 1,441.20 1,451.60 1,416.40 1,421.80
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.00 5,442.00 87.60 16.4 58,554
Last Trade Time Trade Type Trade Size Trade Price Currency
18:45:01 O 1,471 1,438.14 GBX

Gsk (GSK) Latest News

More Gsk News
Gsk Investors    Gsk Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 JPMORGAN CLAVERHOUSE INVESTMENT TRUST PLC 2.90% 2022-12-31
 BMO UK HIGH INCOME TRUST PLC 6.62% 2022-05-31

Gsk (GSK) Discussions and Chat

Gsk Forums and Chat

Date Time Title Posts
03/2/202314:39Glaxosmithkline - The recovery31,511
03/1/202320:21GLAXOSMITHKLINE WITH CHARTS & NEWS187
01/9/202214:17GSK - just mucking around3
24/8/202214:27GlazoSmithKline - News & Information136
23/1/202114:27In Rude Health!1

Add a New Thread

Gsk (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
18:45:021,438.141,47121,155.04O
18:03:061,431.043,89755,767.47O
18:00:001,438.8649,471711,817.44O
17:56:081,439.6025,491366,968.44O
17:56:081,439.605,48979,019.64O
View all Gsk trades in real-time

Gsk (GSK) Top Chat Posts

Top Posts
Posted at 03/2/2023 08:20 by Gsk Daily Update
Gsk Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,427.40p.
Gsk Plc has a 4 week average price of 1,385.20p and a 12 week average price of 1,310.60p.
The 1 year high share price is 1,824.40p while the 1 year low share price is currently 1,283.20p.
There are currently 4,067,353,132 shares in issue and the average daily traded volume is 22,082,881 shares. The market capitalisation of Gsk Plc is £58,553,615,688.27.
Posted at 02/2/2023 10:01 by tradermichael
How is all this getting 'missed' by investors?

Even before GSK's corporate reshaping, which culminated with last summer's Haleon spinoff, the company has long held a leading presence in the HIV field via its ViiV Healthcare joint venture. Within the HIV franchise, GSK's new long-acting injectable therapy Cabenuva started to come into its own in 2022. The drug generated 340 million pounds last year, a sizable jump from 38 million pounds in 2021, when it won its initial FDA approval in January of that year.

Also,
Apretude, the company’s long-acting HIV prevention drug, has seen “very strong” demand after its approval in late 2021, Walmsley said Wednesday. Its sales totaled 41 million pounds in 2022. Like Cabenuva, GSK says it has negotiated favorable coverage for the drug in the U.S., so the company expects the launch to continue to gain steam in 2023.

Also,
Vaccines are another major financial driver for the company. GSK's star vaccine, Shingrix for shingles, suffered from a pandemic slowdown in 2020 and 2021, but the product is rolling once again. Riding a “post-pandemic rebound,” Shingrix delivered a record year in 2022, Chief Commercial Officer Luke Miels said a recent call. Sales reached 2.9 billion pounds last year, a whopping 60% increase from 2021.

Also,
GSK is also anticipating another big vaccine launch this year. The drugmaker submitted its respiratory syncytial virus vaccine candidate to regulators in the U.S., Europe and Japan. The shot is expected to become a blockbuster and vie for market share in this new arena against players such as Pfizer, Sanofi and Moderna.

Posted at 25/1/2023 11:17 by tradermichael
This is holding the share price back:

Among the state court cases naming GSK, a trial in California is currently scheduled to begin 13 February 2023 and a trial is currently scheduled to begin in Madison County, Illinois in February 2023.

Given the early stage of this litigation, it is not possible to quantify or reliably estimate what liability (if any) GSK or any other parties may have in this litigation.

A favourable result will see the share price absolutely rocket .... ;o)

Posted at 05/12/2022 16:10 by geckotheglorious
Bilster1
last week.

GSK is a potential buyout candidate for Novartis - Intron Health”
GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London.

The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology.

In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal.

Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025.
The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition.

hTTps://seekingalpha.com/news/3912660-gsk-stock-gains-on-buyout-claims-linked-to-novartis?

Posted at 05/12/2022 14:55 by geckotheglorious
The ADRs of GSK plc (NYSE:GSK) dropped ~1% pre-market Monday after Bank of America downgraded its shares to Underperform from Neutral, arguing that the British drugmaker remains the firm’s least preferred name among the European majors.

Despite an “undemanding” PE multiple for 2024, “we see insufficient catalysts to rerate (GSK) shares near-term,” the analysts led by Graham Parry wrote, slashing their price target on the stock to 1450p from 1640p.

Noting the ~ £4B free cash flow the company generates, the analysts expect claims related to heartburn medication Zantac to weigh on GSK shares which, according to the analysts, more than discount their base case $4B liability risk.

Despite encouraging Phase 3 data, the analysts see no reason for GSK’s RSV vaccine to outcompete a rival shot from Pfizer (PFE). They also point out that the company has indicated a slower ramp for the RSV vaccine compared to its shingles vaccine Shingrix given the need to educate the public/physicians on the disease.

“While encouraged by GSK’s strong RSV vaccine PIII data we view Pfizer’s vaccine as credible competition given little to no perceived differentiation on efficacy and worse reactogenicity (tolerability) for GSK,” the team wrote.

They also argue that the company’s key franchises remain under pressure and a weak pipeline is unlikely to avoid an upcoming patent cliff in 2028/29E for HIV medication dolutegravir made worse by recent setbacks, including the recall of blood cancer therapy Blenrep.

hTTps://seekingalpha.com/news/3913915-gsk-cut-to-underperform-at-bank-of-america-says-least-preferred-european-major?

Posted at 30/11/2022 20:22 by geckotheglorious
”GSK is a potential buyout candidate for Novartis - Intron Health”
GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London.

The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology.

In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal.

Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025.
The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition.

hTTps://seekingalpha.com/news/3912660-gsk-stock-gains-on-buyout-claims-linked-to-novartis?

Posted at 25/11/2022 08:08 by alibizzle
Roll on.2023 , GSK share price has been a disaster this year . Even with good news it falls
Posted at 11/11/2022 14:42 by geckotheglorious
GSK drops as UBS cuts to Sell on 2027 “bottleneck”

GSK (NYSE:GSK) lost ~4% pre-market Friday after UBS downgraded the British drugmaker to Sell from Hold, questioning the durability of the company’s HIV franchise and revenue from its shingles vaccine Shingrix beyond 2027.

The analysts led by Michael Leuchten estimate a ~20% revenue hit to the company when Shingrix reaches the peak penetration in the U.S. catch-up population in 2027 and HIV therapy dolutegravir faces a patent cliff around the same timeframe.

The analysts think the current consensus for GSK (GSK) fails to recognize the uncertainty over the HIV franchise and implies more than £2B Shingrix revenue than feasible.

The company has time to adjust R&D options and earmark additional capital (£20B – £30B) to tide over the 2027 “bottleneck,” but “this could mean earnings dilution,” the team added, lowering the 12-month price target on GSK (GSK) to 1,300p from 1,820p.

hTTps://seekingalpha.com/news/3906392-gsk-drops-as-ubs-cuts-to-sell-on-2027-bottleneck?

Posted at 03/11/2022 09:06 by stewart64
I wasn't a holder of GSK on demerger day, so didn't go into the mechanics at that time. But wondered if someone can answer this query please. I understand that 5 shares in old GSK became 4 shares in new GSK. Yet Haleon is worth considerably more than one quarter of new GSK. Therefore why didn't the price of new GSK go down on demerger day? Or did the price adjustment occur later and by what factor.

As I'm assuming comparing the old and new GSK price isn't comparing like with like?

Posted at 02/11/2022 10:24 by tradermichael
Zantac
The Zantac litigation continues in federal and state courts in the
United States. GSK's position on the scientific validity of these
cases has not changed since the last reporting period. GSK will continue
to defend all claims vigorously.

GSK has been named as a co-defendant in approximately 4,100 filed
personal injury cases in federal and state court. There are approximately
77,000 plaintiffs named in these cases. A significant majority of
these plaintiffs were named in a series of multi-plaintiff complaints
recently filed in Delaware state court and most of these plaintiffs
were previously in the Multidistrict Litigation (MDL) Census Registry
in the Southern District of Florida. They were removed because they
allege a cancer other than the 5 cancers being pursued by the MDL
plaintiffs. In the MDL, plaintiffs originally identified 10 different
types of cancers they wished to pursue. Plaintiffs subsequently dropped
5 of the 10 cancers, and they are proceeding only as to bladder,
esophageal, gastric, liver, and pancreatic, although plaintiffs in
state courts continue to pursue claims beyond the 5 designated cancers.
There are approximately 33,000 unfiled claims relating to GSK and
other co-defendants concerning the 5 designated cancers in the MDL
Census Registry. There are also over 2,000 California state court
cases subject to an agreement between GSK and the plaintiffs which
suspends the statute of limitations to allow the plaintiffs to bring
their claims at a later date. These filed and unfiled counts are
subject to change.

As planned, in September and October 2022, the MDL Court held hearings
on the admissibility of each side's general causation expert witnesses
("Daubert hearings"). Based on the 12 epidemiological studies conducted
looking at human data regarding the use of ranitidine, the scientific
consensus is that there is no consistent or reliable evidence that
ranitidine increases the risk of any type of cancer. The 12th additional
epidemiologic study (Wang et al. (2022)) was recently released. When
comparing ranitidine to an active comparator (famotidine), Wang 2022
found a statistically significant increased risk with regard to liver
cancer (Hazard Ratio 1.22, 95% Confidence Interval 1.06-1.40) and
no statistically significant increased risk for the remaining 4 cancers
pursued in the MDL. Consistency across available epidemiological
evidence, particularly where reported potential associations are
modest, is critical for drawing reliable conclusions about causation.
The parties await a decision from Judge Robin L. Rosenberg.

In the California Zantac litigation Cases JCCP 5150 (JCCP), the Court
will hold a Sargon hearing on 25 January 2023 regarding the admissibility
of expert witnesses, including general causation expert witnesses,
for the first bellwether trials. The first bellwether trial is expected
to start on 13 February 2023 in the California JCCP.

The Illinois Supreme Court recently consolidated all Illinois ranitidine
cases in Cook County for pretrial proceedings with trial dates to
be set, including the previously scheduled Madison County trial.

Given the complex ownership and marketing of Zantac prescription
and over-the-counter (OTC) medicine over many years, numerous claims
involve several defendants. As a result, some defendants have served
one another, including GSK, with notice of potential indemnification
claims about possible liabilities connected particularly with Zantac
OTC. Given the early stage of the proceedings, GSK cannot meaningfully
assess what liability, if any, it may have, nor can it meaningfully
assess the liability of other parties under relevant indemnification
provisions.

Further information regarding the litigation can be found in GSK's
11 August 2022 and 16 August 2022 statements.

Posted at 13/10/2022 18:19 by alibizzle
GSK share price says 1331 here but when I google it it says 1373 ? Also online it says that haleon share price could collapse to 9pence next year so should I sell now ?
Gsk share price data is direct from the London Stock Exchange
Your Recent History
LSE
GSK
Gsk
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230203 23:47:48